Matinas BioPharma Holdings (MTNB) Asset Writedowns and Impairment (2015 - 2019)
Matinas BioPharma Holdings (MTNB) posted quarterly Asset Writedowns and Impairment of $110277.0 for Q1 2019, up 551.52% year-over-year from $16926.0 in Q1 2018, and up 912.83% quarter-over-quarter from $10888.0 in Q4 2018.
Matinas BioPharma Holdings (MTNB) Asset Writedowns and Impairment (2015 - 2019) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Asset Writedowns and Impairment for 5 consecutive years, with $110277.0 the latest figure, recorded in Q1 2019.
- In Q1 2019, Asset Writedowns and Impairment rose 551.52% year-over-year to $110277.0; the TTM figure through Mar 2019 stood at $150501.0 (down 13.51% YoY), while the FY2024 annual figure was $2.3 million, changed N/A from the prior year.
- Asset Writedowns and Impairment rose to $110277.0 in Q1 2019 per MTNB's latest filing, from $10888.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $110277.0 in Q1 2019 and bottomed at $14.0 in Q2 2017.
- Historically, Asset Writedowns and Impairment has averaged $22417.4 across 5 years, with a median of $8232.0 in 2015.
- Annual changes were most pronounced in 2017 — Asset Writedowns and Impairment plunged 98.13% — and 2018, when it soared 119050.0%.
- Matinas BioPharma Holdings' Asset Writedowns and Impairment stood at $993.0 in 2015, then tumbled by 73.92% to $259.0 in 2016, then surged by 23040.54% to $59934.0 in 2017, then plunged by 81.83% to $10888.0 in 2018, then surged by 912.83% to $110277.0 in 2019.
- Business Quant data shows MTNB's Asset Writedowns and Impairment at $110277.0 in Q1 2019, $10888.0 in Q4 2018, and $12655.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2019 | 110,277.00 |
| Mar 31, 2019 | 110,277.00 |
| Dec 31, 2018 | 10,888.00 |
| Dec 31, 2018 | 10,888.00 |
| Sep 30, 2018 | 12,655.00 |
| Sep 30, 2018 | 12,655.00 |
| Jun 30, 2018 | 16,681.00 |
| Jun 30, 2018 | 16,681.00 |
| Mar 31, 2018 | 16,926.00 |
| Mar 31, 2018 | 16,926.00 |
| Dec 31, 2017 | 59,934.00 |
| Dec 31, 2017 | 59,934.00 |
| Sep 30, 2017 | 97,142.00 |
| Sep 30, 2017 | 97,142.00 |
| Jun 30, 2017 | 14.00 |
| Jun 30, 2017 | 14.00 |
| Mar 31, 2017 | 259.00 |
| Mar 31, 2017 | 259.00 |
| Dec 31, 2016 | 259.00 |
| Dec 31, 2016 | 259.00 |